News & Events

Press Releases

Show All

January 2019

January 8, 2019 FUJIFILM Cellular Dynamics Inc. Launches New Product iCell Microglia, an iPSC-Derived Neural Cell TypeDownload PDF

hiPSC-derived microglia are utilized with the aim of advancing research to fulfill unmet medical needs for patients with neurodegenerative diseases

 MADISON, Wis., January 08, 2019 — FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and tissue-specific cells differentiated  from iPSCs, has announced the launch of its newest product, iCell® Microglia. Microglia are the immune cells of the central nervous system responsible for fundamental physiological and pathological processes. Differentiated from human iPSCs, iCell Microglia will be used in life science research to enable the study and development of therapies for degenerative neurological diseases such as Alzheimer’s disease…

January 3, 2019 FUJIFILM Cellular Dynamics to Establish New Facility for Production of Human iPS Cell Therapy ApplicationsDownload PDF

Fujifilm is investing in the cGMP-compliant facility located in Madison, Wisconsin with the goal to begin operations by March 2020

MADISON, Wis., January 3, 2019 — FUJIFILM Cellular Dynamics, Inc. (FCDI), a US subsidiary of FUJIFILM Corporation (President: Kenji Sukeno) and a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, has announced an investment of about $21 million to open a new cGMP-compliant  production facility with the goal of industrializing iPS cell manufacturing for regenerative medicine therapies. The facility will support FCDI’s internal cell therapeutics pipeline and will also serve as a Contract Development and Manufacturing Organization (CDMO) for iPS cell products.

June 2018

June 6, 2018 Fujifilm Cellular Dynamics Announces Agreement with UCI to Commercialize iPSC-Derived Microglia and Media Formulation

FUJIFILM Cellular Dynamics, Inc., licenses University of California – Irvine’s technologies for derivation of microglia

MADISON, Wis., June 6, 2018— FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and differentiated tissue-specific iPSCs, announced today that it has entered into an exclusive patent license agreement with the University of California – Irvine (UCI) through its offices at UCI Applied Innovation to license and commercialize UCI’s technologies for derivation of microglia in the commercial research field and also a non-exclusive patent license agreement to commercialize microglia media formulation. The license of UCI’s groundbreaking technology enables FCDI to differentiate pluripotent stem cells into microglia cells, a brain cell type that plays a critical role in preserving the function of the brain. With this technology, FCDI intends to develop an iPSC-derived microglia product with media, which will be critical to enabling the study of degenerative neurological diseases such as Alzheimer’s disease.

February 2018

February 8, 2018 Fujifilm and Takeda Announce Collaboration to Develop Regenerative Medicine Therapies using Cardiomyocytes Derived from iPSC

February 8, 2018 – FUJIFILM Corporation (“Fujifilm”, President: Kenji Sukeno) and Takeda Pharmaceutical Company Ltd., (“Takeda”, CEO: Christophe Weber) today announced a collaboration to develop regenerative medicine therapies using cardiomyocytes derived from iPSC for the treatment of heart failure.

December 2017

December 22, 2017 Cellular Dynamics International Sends Human iPSC-Derived Cardiomyocytes To International Space Station On NASA Resupply Mission

MADISON, Wis., Dec. 27, 2017 — Cellular Dynamics International (CDI), a FUJIFILM company, the leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and differentiated tissue-specific iPSC-cells, announced that its iCell® Cardiomyocytes were launched into space via SpaceX’s 13th commercial resupply services mission to the International Space Station on Dec.15, 2017. The purpose of the scientific research project utilizing CDI’s iCell Cardiomyocytes in space is to validate the function of NASA’s new Bioculture System for automated cell culture on the International Space Station and to study human cardiac cell function in microgravity.

September 2017

September 20, 2017 CDI Signs Agreement with Nanion to Enhance Mutual Offerings for Researchers

Madison, Wisconsin, September 20, 2017— Cellular Dynamics International (CDI), a FUJIFILM company, the leading developer and manufacturer of differentiated cells derived from human induced pluripotent stem cells (iPSCs), and Nanion Technologies GmbH (Nanion), a leading provider of instrumentation for ion channel drug discovery and screening, announced today that they have entered into a joint marketing agreement. The mutual partnership will offer research customers access to CDI’s suite of human iPSC-derived tissue cells paired with the high performance instrument platforms from Nanion to drive functional readouts on human cell models.

September 13, 2017 Cellular Dynamics International Presents Annual iForum Meetings Focused on New Applications and Uses for Differentiated Human iPS Cells

MADISON, Wis. — Cellular Dynamics International (CDI), a FUJIFILM company, today announced that it will host the iForum® 2017 meetings at The Buck Institute (Novato, CA) on September 14, 2017, Harvard Medical School (Boston, MA) on September 21, 2017, and at Imperial College (London, U.K.) on September 28, 2017. The annual iForum meetings provide attendees with an opportunity to connect with thought leaders from academia, government, biotech, and pharma to discover new applications and innovative uses for differentiated induced pluripotent stem cells (iPSC) through interactive, data-driven presentations.

April 2017

April 19, 2017 Cellular Dynamics International Collaboration Agreement with Harvard Stem Cell Institute

Madison, Wisconsin, April 19, 2017— Cellular Dynamics International (CDI), a FUJIFILM company and a leading developer and manufacturer of induced pluripotent stem cells (iPS), today announced it has signed a collaboration agreement with the Harvard Stem Cell Institute (HSCI), a novel network of stem cell scientists that extends from the University to its affiliated hospitals and the biomedical industry. The objective of the new partnership is to increase the availability of iPS cells and services to the HSCI network and the research community at large.

April 18, 2017 Cellular Dynamics International Signs Distribution Deal with STEMCELL Technologies

MADISON, Wis.–(BUSINESS WIRE)– Cellular Dynamics International (CDI), a FUJIFILM company and a leading developer and manufacturer of induced pluripotent stem cell-derived products, today announced it has signed a distribution agreement with STEMCELL Technologies, a world leader in iPS cell culture media.

“This joint agreement with STEMCELL Technologies will make iPSC technology widely available to researchers worldwide, helping advance biological research leading to cellular therapies and drug discovery,” said Dr. Bruce Novich, Division President-CNBD for FUJIFILM Holdings America Corporation and Executive Vice President and General Manager for CDI. “We believe that STEMCELL Technologies, a leading developer, manufacturer and seller of stem cell related products, is an ideal partner for CDI, because their global sales and distribution infrastructure delivers to an established and an emerging customer base, which translates into faster access to and deeper penetration of CDI’s leading edge technologies and products.”

September 2016

September 28, 2016 Cellular Dynamics International Launches Opsis Therapeutics to Develop Cell Therapies for Treatment of Retinal DiseasesDownload PDF

MADISON, WIS, September 28, 2016 – Cellular Dynamics International, Inc. (CDI), a FUJIFILM company and the leading developer and manufacturer of induced pluripotent stem cell (iPSC) products, today announced a new venture, named Opsis Therapeutics. Formed on July 31, Opsis Therapeutics is focused on discovering and developing novel medicines to treat patients suffering from retinal diseases. The Opsis Therapeutics team brings deep expertise and a track record of developing breakthrough technologies and building next-generation cell therapeutic programs. The venture has been founded in partnership with David Gamm, M.D., Ph.D., a world leader and pioneer in the differentiation and transplantation of iPSC-derived retinal cells.

Pageof 12